Objectives: Information is emerging on the clin. impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (PwCF). This survey aims to characterize SARS-CoV-2 infection (COVID-19) in PwCF within the All Wales Adult Cystic Fibrosis Center (AWACFC). Methods: Patient data was retrospectively collated using electronic and written healthcare records. Age, sex, FEV1% pre-infection, chest radiograph (CXR) appearances, symptoms, clin. progress, CFTR modulator use, COVID-19 PCR results and COVID vaccination status were recorded. An AWACFC CF COVID-19 "Virtual Ward" management flowchart was established to standardise and optimize patient care. Results: Thirty-eight PwCF in AWACFC had COVID-19 in 2020 (n = 10) and 2021 (n = 28). Of those infected, 20 (52%) were male, age range 17-50 yr, FEV1% range 38-113%, 26 (68%) were on CTFR modulators, with 4 (11%) post-lung transplant. Of the 2021 cohort (n = 28), 21 (75%) were fully vaccinated, 1 (4%) partially vaccinated, and 6 (21%) unvaccinated at time of infection. Most had mild-moderate symptoms, only 2 (5%) reportedly asymptomatic. Treatment varied: 24 (63%) required oral antibiotics at home (for symptoms or precautionary), 1 received antiviral molnupiravir, 4 (11%) required admission. Of the 4 admitted, 3 (75%)were post-lung transplant: 1 required pos. pressure oxygenation, 1 underwent extended invasive ventilation. Of those not admitted (n = 34) there was no change in post COVID-19 CXR appearances in 16 (47%), 3 (9%) registered CXR changes, the rest are awaiting follow-up CXR. There were no deaths or recorded reinfections. Conclusion: The contrast in COVID-19 incidence between 2020 and 2021 may reflect national shielding for clin. vulnerable groups in the UK in 2020, or emergence of new variants. The majority of PwCF had mildmoderate symptoms and good recovery from COVID-19. Most of those hospitalised were post-transplant, consistent with known risks in this clin. extremely vulnerable cohort.